Adlai Nortye Ltd. (Nasdaq:ANL)
Health Care/Life Sciences • Pharmaceuticals
CIK 1944552
Company
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.
Address
Building 6 & 8
1008 Xiangwang Street
Yuhang District
Hangzhou, Zhejiang 311100
Building 6 & 8
1008 Xiangwang Street
Yuhang District
Hangzhou, Zhejiang 311100
Employees
None
None
Key Executives
Board Of Directors
Chairman & Chief Executive Officer Yang Lu EMBA |
Director Ji Ping MD |
Director Lars E Birgerson MD, PhD |
Independent Director Shao Rong Liu MBA |
Independent Director Cai Cheguo |
Independent Non-Executive Director Ming Lun Tse |
SEC filings
Date | Form | Event |
---|---|---|
8 Aug, 2024 | 6-K | |
3 Jul, 2024 | 6-K | |
27 Jun, 2024 | 6-K | |
24 May, 2024 | 6-K | |
13 May, 2024 | S-8 | |
19 Apr, 2024 | 20-F | |
2 Apr, 2024 | 6-K | |
4 Mar, 2024 | SC 13G | |
15 Feb, 2024 | SC 13G | |
15 Feb, 2024 | SC 13G | |
14 Feb, 2024 | SC 13G | |
31 Jan, 2024 | SC 13G | |
13 Oct, 2023 | SC 13G | |
29 Sep, 2023 | 424B4 | IPO completed |
28 Sep, 2023 | CERT | |
28 Sep, 2023 | EFFECT | |
27 Sep, 2023 | CORRESP | |
27 Sep, 2023 | F-1/A | |
27 Sep, 2023 | CORRESP | |
27 Sep, 2023 | CORRESP | |
20 Sep, 2023 | UPLOAD | |
12 Sep, 2023 | CORRESP | |
12 Sep, 2023 | F-1/A | |
18 Aug, 2023 | 8-A12B | |
16 Aug, 2023 | UPLOAD | |
14 Aug, 2023 | CORRESP | |
14 Aug, 2023 | F-1/A | |
10 Aug, 2023 | CORRESP | |
10 Aug, 2023 | F-1/A | |
7 Aug, 2023 | 8-A12B | |
27 Jul, 2023 | CORRESP | |
27 Jul, 2023 | F-1 | |
29 Jun, 2023 | UPLOAD | |
22 Jun, 2023 | DRSLTR | |
22 Jun, 2023 | DRS/A | |
19 May, 2023 | UPLOAD | |
11 May, 2023 | DRSLTR | |
11 May, 2023 | DRS/A | |
27 Apr, 2023 | UPLOAD | |
14 Apr, 2023 | DRSLTR | |
14 Apr, 2023 | DRS/A | |
13 Mar, 2023 | UPLOAD | |
27 Feb, 2023 | DRSLTR | |
27 Feb, 2023 | DRS/A | |
18 Jan, 2023 | UPLOAD | |
21 Dec, 2022 | DRSLTR | |
21 Dec, 2022 | DRS |
Last update:2024-03-06 12:16:15.752754
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.